
    
      This study is an open-label, multi-center, dose-ranging study to characterize the safety,
      tolerability, preliminary efficacy, and PK/PD of up to four dose levels of BNZ-1 administered
      weekly by IV infusion to adults diagnosed with LGL or CTCL. The study has 5 periods:

        -  Screening Period

        -  4-week Treatment Period

        -  3-month Treatment Extension Period

        -  Long-term Extension Period (open-ended)

        -  6-week Follow-up Period Subjects will be screened for eligibility within 30 days of
           study Day 1 (first dosing day of the 4-Week Treatment Period).
    
  